Renato G Martins
Virginia Commonwealth University · 123 works · 15,928 citations · h-index 31
Top works
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
- Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal
- NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
- Validation and Implementation of Targeted Capture and Sequencing for the Detection of Actionable Mutation, Copy Number Variation, and Gene Rearrangement in Clinical Cancer Specimens
- Non–Small Cell Lung Cancer, Version 2.2013
- Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer
- Phase II Study of Daily Sunitinib in FDG-PET–Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation
- Non–Small Cell Lung Cancer
- A Randomized, Phase II, Biomarker-Selected Study Comparing Erlotinib to Erlotinib Intercalated With Chemotherapy in First-Line Therapy for Advanced Non–Small-Cell Lung Cancer
- Anti–PD-1 and Anti–PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes
- Non-Small Cell Lung Cancer Guidelines
- Head and Neck Cancers, Version 2.2014
- Non–Small Cell Lung Cancer, Version 1.2015
- Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes
- A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine‐refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment
- Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial
- Head and Neck Cancers, Version 2.2013
- Characterizing Potentially Preventable Cancer- and Chronic Disease–Related Emergency Department Use in the Year After Treatment Initiation: A Regional Study
- Treatment of Recurrent Squamous Cell Carcinoma of the Skin With Cetuximab